ESSA Pharma (EPI) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free EPI Stock Alerts Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineESSA Bancorp Inc ESSAmorningstar.com - May 1 at 11:25 PMDoes Insurance Cover EpiPens?msn.com - April 27 at 12:13 AMESSA Pharma Inc (EPIX)uk.investing.com - April 7 at 8:09 AMEssa Pharma initiated with bullish view at JonesResearch, here's whyrealmoney.thestreet.com - January 30 at 9:32 PMEPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…finance.yahoo.com - January 26 at 6:04 PMWhat's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?msn.com - January 26 at 6:04 PMESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposiumfinanznachrichten.de - January 25 at 7:37 PMESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposiumfinance.yahoo.com - January 25 at 7:37 PMESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...finance.yahoo.com - December 12 at 12:57 PMDirector Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Sharesfinance.yahoo.com - November 23 at 2:39 PMESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistanceseekingalpha.com - November 7 at 7:17 PMAnalysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)markets.businessinsider.com - October 24 at 9:30 AMProstate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)benzinga.com - October 6 at 11:38 PMESSA Pharma files for $200M mixed shelf offering - filingseekingalpha.com - September 20 at 1:00 AMOppenheimer Reiterates Essa Pharma (EPIX) Outperform Recommendationmsn.com - August 9 at 5:12 PMWhy are EpiPens still so expensive?msn.com - April 4 at 8:50 AMESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)finance.yahoo.com - February 13 at 6:22 PMEPIX: Advancing Multiple Clinical Trials in 2023…finance.yahoo.com - December 19 at 2:14 PMESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancerseekingalpha.com - November 16 at 12:04 AMEssa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trialsmarketwatch.com - October 31 at 11:43 AMESSA drops 26% as Johnson & Johnson ends trial enrollment for lead assetseekingalpha.com - October 31 at 11:43 AMESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposiumfinance.yahoo.com - October 26 at 5:28 PMESSA Pharma Surges 152% on Study Results for Lead Drug Candidatemarketwatch.com - October 26 at 5:28 PMPromontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposiumfinance.yahoo.com - October 26 at 12:27 PMESSA Pharma jumps 91% on Phase 1/2 data for prostate cancer therapyseekingalpha.com - October 26 at 12:27 PMEPIX: Multiple Ongoing Studies of EPI-7386…finance.yahoo.com - August 10 at 2:16 PMESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancerfinance.yahoo.com - June 28 at 3:59 PMEpiEndo: Successful Completion of Phase I Study for Lead Asset EP395apnews.com - May 18 at 8:23 PMHypertension Epidemiology Forecast Report 2022: Focus on US, Germany, Spain, Italy, France, UK, and Japan, 2019-2032 - ResearchAndMarkets.comfinance.yahoo.com - January 22 at 11:46 PMHypertension Epidemiology Forecast Report 2022: Focus on US, Germany, Spain, Italy, France, UK, and Japan, 2019-2032 - ResearchAndMarkets.comfinance.yahoo.com - January 22 at 11:46 PMHypovolemic Shock Epidemiology Forecast Report 2022: Focus on US, Germany, Spain, Italy, France, UK, and Japan, 2019-2032 - ResearchAndMarkets.comfinance.yahoo.com - January 22 at 6:39 PMSeagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancerfinance.yahoo.com - January 21 at 10:37 PMJosiah-Jordan James doubtful to return for Tennessee basketball vs. Vanderbiltyahoo.com - January 20 at 9:07 PMESSA Pharma begins dosing of EPI-7386 in phase 1/2 prostate cancer studyseekingalpha.com - January 19 at 2:20 PM3EPIX : ESSA Pharma Announces First Patient Dosed In Phase 1/2 Clinical...benzinga.com - January 19 at 9:19 AMEPIX: Combination Studies Set to Initiate…markets.businessinsider.com - November 22 at 3:50 PMESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386finance.yahoo.com - October 7 at 9:51 AMTasrif Pharmaceutical Announces Grant of U.S. Patent for Humanized Monoclonal Antibodies against the Poliovirus Receptorfinance.yahoo.com - August 27 at 9:21 PMPharmaceutical Lipids Market Is Forecasted To Represent Noteworthy Share During Forecast Period 2021-2028: Acumen Research And Consultingfinance.yahoo.com - August 27 at 9:21 PMGlobal Castrate Resistant Prostate Cancer (CRPC) Market to Surpass US$ 16.4 Billion by 2028, Says Coherent Market Insights (CMI)sg.finance.yahoo.com - July 22 at 7:10 PM Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent dollar warning (Ad)Your 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today. Find out for free here. EPI Media Mentions By Week EPI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPI News Sentiment▼0.000.36▲Average News Sentiment EPI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPI Articles This Week▼20▲EPI Articles Average Week Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:EPI) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.